Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer

Susanna V. Ulahannan, Julie R. Brahmer

Research output: Contribution to journalReview articlepeer-review

Abstract

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)325-337
Number of pages13
JournalCancer Investigation
Volume29
Issue number4
DOIs
StatePublished - May 1 2011

Keywords

  • Antiangiogenesis inhibitors
  • Bevacizumab
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this